<DOC>
	<DOC>NCT00851227</DOC>
	<brief_summary>A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function</brief_summary>
	<brief_title>Study to Compare Conivaptan in Subjects With Mild &amp; Moderate Liver Impairment Versus Subjects With Normal Liver Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Subjects with Normal Hepatic Function: Weighs at least 45 kg Body mass index between 18 and 40 kg/m2 inclusive Must have normal hepatic function Hepatic Impaired Subjects: Weighs at least 45 kg Meets criteria for mild or moderate hepatic impairment defined by ChildPugh method Body mass index between 18 and 40 kg/m2 inclusive Subjects with Normal Hepatic Function: Smokes more than 10 cigarettes per day Known to be HIV positive or has HIV antibodies Has clinically significant history or presence of illness, malignancy, or immunodeficiency Is Hepatitis A, B, or C positive Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration History of substance abuse within 6 months prior to screening Hepatic Impaired Subjects: Has history or presence of biliary obstruction or biliary disease, hepatic encephalopathy, advanced acidities, portal hypertension, or biliary liver cirrhosis Is hypovolemic or has evidence of orthostatic hypotension Smokes more than 10 cigarettes per day Known to be HIV positive or has HIV antibodies Has clinically significant history or presence of illness, malignancy, or immunodeficiency Has clinically significant history or presence of GI symptoms other than those associated with moderate hepatic impairment Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration History of substance abuse within 6 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Protein Binding</keyword>
	<keyword>Conivaptan</keyword>
	<keyword>Vaprisol</keyword>
	<keyword>Liver Disease</keyword>
</DOC>